替格瑞洛联合阿托伐他汀与阿司匹林在急性冠状动脉综合症经皮冠状动脉介入术术后应用效果及安全性  

Effect and safety of tigrelol combined with atorvastatin and aspirin after percutaneous coronary intervention for acute coronary syndrome

作　　者：邓乐华 蔡晓霞 王蔚浩 林海云 DENG Le-hua;CAI Xiao-xia;WANG Wei-hao;LIN Hai-yun(Department of Cardiology,Dongguan eastern central hospital,Dongguan Guangdong 523560,China;Department of physical examination,Dongguan eastern central hospital,Dongguan Guangdong 523560,China)

机构地区：[1]东莞市东部中心医院心血管内科,广东东莞523560 [2]东莞市东部中心医院体检科,广东东莞523560

出　　处：《医学食疗与健康》2022年第1期63-65,共3页Medical Diet and Health

摘　　要：目的:分析替格瑞洛联合阿托伐他汀与阿司匹林在急性冠状动脉综合症经皮冠状动脉介入术术后应用效果及安全性。方法:回顾性分析2017年1月至2020年6月期间我院收治的62例急性冠状动脉综合症患者的临床资料,按治疗方法的不同将其分为对照组和观察组,每组各31例;所有患者均接受经皮冠状动脉介入术治疗,术后对照组给予阿司匹林+氯吡格雷+阿托伐他汀治疗;观察组给予阿司匹林+替格瑞洛+阿托伐他汀治疗,对比两组治疗前、治疗3个月后的低密度脂蛋白胆固醇(LDL-C)、C反应蛋白(CRP)、B型尿钠肽(BNP)、左室射血分数(LVEF),两组再狭窄发生率、心血管不良事件发生率,对比两组患者临床治疗效果。结果:治疗后,观察组的LDL-C、CRP、BNP水平均低于对照组,而LVEF水平高于对照组(P<0.05)。观察组的再狭窄发生率、心血管不良事件发生率均低于对照组(P<0.05),观察组临床治疗后的总有效率93.55%高于对照组80.65%,差异显著(P<0.05)。结论:将替格瑞洛、阿托伐他汀、阿司匹林联合应用于急性冠状动脉综合症患者经皮冠状动脉介入术术后,能显著调节血脂,改善血流速度,消除炎症,减少心肌损伤、再狭窄的发生,降低心血管不良事件发生风险,安全性高。Objective:To analyze the effect and safety of tegranolol combined with atorvastatin and aspirin after percutaneous coronary intervention for acute coronary syndrome.Methods:The clinical data of 62 patients with acute coronary syndrome treated in our hospital from January 2017 to June 2020 were analyzed retrospectively.According to different treatment methods,they were divided into control group and observation group,with 31 cases in each group;All patients received percutaneous coronary intervention.The control group was treated with aspirin + clopidogrel + atorvastatin;The observation group was treated with aspirin + tigrelol + atorvastatin.The low density lipoprotein cholesterol(LDL-C),C-reactive protein(CRP),B-type natriuretic peptide(BNP),left ventricular ejection fraction(LVEF),the incidence of restenosis and adverse cardiovascular events were compared before and 3 months after treatment.Results:After treatment,the levels of LDL-C,CRP and BNP in the observation group were lower than those in the control group,while the level of LVEF was higher than that in the control group(P<0.05).The incidence of restenosis and adverse cardiovascular events in the observation group were lower than those in the control group(P<0.05).The total effective rate after clinical treatment in the observation group was 93.55% higher than 80.65% in the control group(P<0.05).Conclusion:The combination of ticagrelor,atorvastatin and aspirin in patients with acute coronary syndrome after percutaneous coronary intervention can significantly regulate blood lipid,improve blood flow velocity,eliminate inflammation,reduce myocardial injury and restenosis,reduce the risk of cardiovascular adverse events,and have high safety.

关 键 词：替格瑞洛 阿托伐他汀 阿司匹林 急性冠状动脉综合症 经皮冠状动脉介入术 

分 类 号：R541.4[医药卫生—心血管疾病]